AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Contact
697 Burke Road
Suite 201
CamberwellVIC3124
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
1
Stocks News & Analysis
stocks
ASX giant falls short on copper guidance
Weak copper guidance appears temporary, but valuation concerns remain.
stocks
Pure-play data center share raises capital to fund AI demand
Funding the next wave of data center growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,974.70 | 32.40 | -0.36% |
| CAC 40 | 8,340.11 | 1.30 | 0.02% |
| DAX 40 | 24,846.69 | 15.71 | 0.06% |
| Dow JONES (US) | 51,927.71 | 218.71 | -0.42% |
| FTSE 100 | 10,524.76 | 75.61 | -0.71% |
| HKSE | 25,143.05 | 580.81 | 2.36% |
| NASDAQ | 25,600.67 | 80.42 | 0.32% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,696.03 | 1.35 | 0.01% |
| S&P 500 | 7,463.36 | 5.67 | 0.08% |
| S&P/ASX 200 | 8,791.30 | 31.00 | -0.35% |
| SSE Composite Index | 3,796.28 | 32.13 | 0.85% |